1. Medtech Insight
  2. >>Archive

New dose-counting inhaler from Allen and Hanburys:

Allen & Hanburys (UK) has launched its new dose-counting asthma inhaler, Ventolin Accuhaler, in the UK. It is a multi-dose, breath-operated, dry powder inhaler for the short-acting bronchodilator, Ventolin (salbutamol). The integral counter allows physicians to compare the actual number of doses their patients are taking with the prescribed amount, to see if the therapy needs to be modified. Ventolin Accuhaler costs £5 ($7.5) per pack.

Allen & Hanburys (UK) has launched its new dose-counting asthma inhaler, Ventolin Accuhaler, in the UK. It is a multi-dose, breath-operated, dry powder inhaler for the short-acting bronchodilator, Ventolin (salbutamol). The integral counter allows physicians to compare the actual number of doses their patients are taking with the prescribed amount, to see if the therapy needs to be modified. Ventolin Accuhaler costs £5 ($7.5) per pack.

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Altaviva Approval A Big Win For Medtronic And Millions Struggling With Bladder Control

 
• By Brian Bossetta

The US FDA has approved Medtronic’s Altaviva, a subcutaneous device implanted near the ankle that offers a new treatment option for adults with urge urinary incontinence.

Execs On The Move: September 8–12, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

New Guidelines Support Early Intervention With Edwards TAVR Device Sapien

 
• By Natasha Barrow

The new ESC and EACTS guidelines allow aortic stenosis patients without symptoms to be considered for a transcatheter aortic valve replacement. The move opens the market for Edwards Lifesciences, the only medtech with a Europe and US-approved device for asymptomatic severe aortic stenosis.